Replies to post #148046 on Biotech Values

[acgood]

Thank you both for the replies.

LGND (and MRK) have both said the drug would be advancing to phase 2. An R&D day shortly after the reverse split seems like too long ago for that decision to have been made though - that would be before the data discussion at the MRK R&D day in January 2012:
http://www.biotechduediligence.com/1/post/2012/01/merck-mrk-rd-day-info-re-bace-alzheimers-disease-program.html

masterlongevity - Do you have access to the abstract or poster from this summer's presentation by MRK? Last I checked with the company, LGND did not have it available and the abstracts didn't seem to be online.

[biomaven0]

There's some discussion of Ligand's drug in this presentation from a few years back (see p37):

http://www.faqs.org/sec-filings/100624/LIGAND-PHARMACEUTICALS-INC_8-K/dex991.htm#b

Oral BACE inhibitors that penetrate the blood-brain barrier have been very hard to come by despite a lot of effort.

The dramatic failure of a gamma-secretase inhibitor casts at least a shadow over this target as well.

Peter